Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

957 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Proteomic profiles of peritoneal fluid-derived small extracellular vesicles correlate with patient outcome in ovarian cancer.
Quiralte M, Barquín A, Yagüe-Fernández M, Navarro P, Grazioso TP, Sevillano-Fernández E, Rodriguez-Moreno JF, Balarezo-Saldivar A, Peinado H, Izquierdo E, Millán C, López-Carrasco I, Prieto M, Madurga R, Fernández-Miranda I, Ruiz-Llorente S, García-Donas J. Quiralte M, et al. Among authors: navarro p. J Clin Invest. 2024 Apr 2;134(10):e176161. doi: 10.1172/JCI176161. J Clin Invest. 2024. PMID: 38564289 Free PMC article. Clinical Trial.
Open-label phase II clinical trial of ketoconazole as CYP17 inhibitor in metastatic or advanced non-resectable granulosa cell ovarian tumors: the GREKO (GRanulosa Et KetOconazole) trial, GETHI 2011-03.
Garcia-Donas J, Hurtado A, Garrigos L, Santaballa A, Redondo A, Vidal L, Lainez N, Guerra E, Rodriguez V, Cueva J, Bover I, Palacio I, Rubio MJ, Prieto M, Lopez-Guerrero JA, Rodriguez-Moreno JF, Garcia-Casado Z, Garcia-Martinez E, Taus A, de Castro IP, Navarro P, Grande E; Spanish Group for Research in Orphan, Infrequent Tumors (GETHI). Garcia-Donas J, et al. Among authors: navarro p. Clin Transl Oncol. 2023 Jul;25(7):2090-2098. doi: 10.1007/s12094-023-03085-w. Epub 2023 Jan 28. Clin Transl Oncol. 2023. PMID: 36708371 Clinical Trial.
Randomized phase II clinical trial of ruxolitinib plus simvastatin in COVID19 clinical outcome and cytokine evolution.
Garcia-Donas J, Martínez-Urbistondo D, Velázquez Kennedy K, Villares P, Barquin A, Dominguez A, Rodriguez-Moreno JF, Caro E, Suarez Del Villar R, Nistal-Villan E, Yagüe M, Ortiz M, Barba M, Ruiz-Llorente S, Quiralte M, Zanin M, Rodríguez C, Navarro P, Berraondo P, Madurga R. Garcia-Donas J, et al. Among authors: navarro p. Front Immunol. 2023 Apr 18;14:1156603. doi: 10.3389/fimmu.2023.1156603. eCollection 2023. Front Immunol. 2023. PMID: 37143685 Free PMC article. Clinical Trial.
Impact of the Identification of Nonhuman Genetic Signatures in the Diagnosis and Management of Carcinoma of Unknown Primary.
Barquín García A, Palacios-Zambrano S, Lozano Alarcón F, Paumard-Hernández B, Quiralte Pulido M, Navarro P, Rodríguez L, Salas Villar I, García-Donas J. Barquín García A, et al. Among authors: navarro p. J Natl Compr Canc Netw. 2023 Dec 27;22(1D):e237079. doi: 10.6004/jnccn.2023.7079. J Natl Compr Canc Netw. 2023. PMID: 38150820
Phase II clinical trial assessing the efficacy of enzalutamide in advanced non-resectable granulosa cell ovarian tumors: The GREKO III study (GETHI2016-01).
García-Donas J, Redondo A, Santaballa A, Garrigos L, Rubio MJ, Lainez N, González MI, Cueva JF, Barquin A, Grazioso TP, Hurtado A, Sevillano E, Grande E, Rodriguez-Moreno JF, Navarro P. García-Donas J, et al. Among authors: navarro p. Gynecol Oncol. 2024 Dec;191:233-239. doi: 10.1016/j.ygyno.2024.10.019. Epub 2024 Oct 24. Gynecol Oncol. 2024. PMID: 39454227 Clinical Trial.
Prospective study of the real impact of fusion centered genomic assays in patient management in a national collaborative group: the GETHI-XX-16 study.
Navarro P, Beato C, Rodriguez-Moreno JF, Ruiz-Llorente S, Mielgo X, Pineda E, Navarro M, Bruixola G, Grazioso TP, Viudez A, Fuster J, Nogueron E, Mediano MD, Balaña C, Mendez C, Rodriguez RM, Del Barco Berron S, Gongora B, Carmona-Bayonas A, Garcia-Donas J. Navarro P, et al. Clin Transl Oncol. 2024 Nov 1. doi: 10.1007/s12094-024-03745-5. Online ahead of print. Clin Transl Oncol. 2024. PMID: 39485597
Open-label phase II clinical trial of orteronel (TAK-700) in metastatic or advanced non-resectable granulosa cell ovarian tumors: the Greko II study (GETHI2013-01).
Garcia-Donas J, Garrigos L, Lainez N, Santaballa A, Redondo A, Cueva JF, Rubio MJ, Prieto M, Lopez-Guerrero JA, Garcia-Casado Z, Barquin A, Grande E, Alia EG, Sevillano E, Bover I, Grazioso TP, Sanchez-Escribano R, Hurtado A, Navarro P, Rodriguez-Moreno JF. Garcia-Donas J, et al. Among authors: navarro p. Clin Transl Oncol. 2024 Dec 30. doi: 10.1007/s12094-024-03827-4. Online ahead of print. Clin Transl Oncol. 2024. PMID: 39738931
PBRM1 and KDM5C cooperate to define high-angiogenesis tumors and increased antiangiogenic response in renal cancer.
Santos M, Lanillos J, Caleiras E, Valdivia C, Roldan-Romero JM, Laínez N, Puente J, Beuselinck B, Oudard S, Zucman-Rossi J, Navarro P, Robledo M, Castellano D, de Velasco G, García-Donas J, Rodriguez-Antona C. Santos M, et al. Among authors: navarro p. Am J Cancer Res. 2023 May 15;13(5):2116-2125. eCollection 2023. Am J Cancer Res. 2023. PMID: 37293154 Free PMC article.
CRISPR targeting of FOXL2 c.402C>G mutation reduces malignant phenotype in granulosa tumor cells and identifies anti-tumoral compounds.
Amarilla-Quintana S, Navarro P, Hernández I, Ramos A, Montero-Calle A, Cabezas-Sainz P, Barrero MJ, Megías D, Vilaplana-Martí B, Epifano C, Gómez-Dominguez D, Monzón S, Cuesta I, Sánchez L, Barderas R, García-Donas J, Martín A, Pérez de Castro I. Amarilla-Quintana S, et al. Among authors: navarro p. Mol Oncol. 2025 Jan 8. doi: 10.1002/1878-0261.13799. Online ahead of print. Mol Oncol. 2025. PMID: 39776254 Free article.
957 results